These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

749 related articles for article (PubMed ID: 24478400)

  • 21. TERT rs2736100 A>C SNP and JAK2 46/1 haplotype significantly contribute to the occurrence of JAK2 V617F and CALR mutated myeloproliferative neoplasms - a multicentric study on 529 patients.
    Trifa AP; Bănescu C; Tevet M; Bojan A; Dima D; Urian L; Török-Vistai T; Popov VM; Zdrenghea M; Petrov L; Vasilache A; Murat M; Georgescu D; Popescu M; Pătrinoiu O; Balea M; Costache R; Coleș E; Șaguna C; Berbec N; Vlădăreanu AM; Mihăilă RG; Bumbea H; Cucuianu A; Popp RA
    Br J Haematol; 2016 Jul; 174(2):218-26. PubMed ID: 27061303
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Calreticulin Mutations in Bulgarian MPN Patients.
    Pavlov I; Hadjiev E; Alaikov T; Spassova S; Stoimenov A; Naumova E; Shivarov V; Ivanova M
    Pathol Oncol Res; 2018 Jan; 24(1):171-174. PubMed ID: 28411309
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Frequencies, Laboratory Features, and Granulocyte Activation in Chinese Patients with CALR-Mutated Myeloproliferative Neoplasms.
    Guo H; Chen X; Tian R; Chang J; Li J; Tan Y; Xu Z; Ren F; Zhao J; Pan J; Zhang N; Wang X; He J; Yang W; Wang H
    PLoS One; 2015; 10(9):e0138250. PubMed ID: 26375990
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Quantitative assessment of JAK2 V617F and CALR mutations in Philadelphia negative myeloproliferative neoplasms.
    Gángó A; Mózes R; Boha Z; Kajtár B; Timár B; Király PA; Kiss R; Fésüs V; Nagy N; Demeter J; Körösmezey G; Borbényi Z; Marton I; Szőke A; Masszi T; Farkas P; Várkonyi J; Plander M; Pósfai É; Egyed M; Pál K; Radványi G; Hamed A; Csomor J; Matolcsy A; Alpár D; Bödör C
    Leuk Res; 2018 Feb; 65():42-48. PubMed ID: 29306106
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Validation of a molecular diagnostic assay for CALR exon 9 indels in myeloproliferative neoplasms: identification of coexisting JAK2 and CALR mutations and a novel 9 bp deletion in CALR.
    Murugesan G; Guenther-Johnson J; Mularo F; Cook JR; Daly TM
    Int J Lab Hematol; 2016 Jun; 38(3):284-97. PubMed ID: 27018326
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical validation of a multipurpose assay for detection and genotyping of CALR mutations in myeloproliferative neoplasms.
    Mehrotra M; Luthra R; Singh RR; Barkoh BA; Galbincea J; Mehta P; Goswami RS; Jabbar KJ; Loghavi S; Medeiros LJ; Verstovsek S; Patel KP
    Am J Clin Pathol; 2015 Nov; 144(5):746-55. PubMed ID: 26486739
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A primer on genomic and epigenomic alterations in the myeloproliferative neoplasms.
    Rampal R; Levine RL
    Best Pract Res Clin Haematol; 2014 Jun; 27(2):83-93. PubMed ID: 25189720
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevalence and phenotypes of
    Cordua S; Kjaer L; Skov V; Pallisgaard N; Hasselbalch HC; Ellervik C
    Blood; 2019 Aug; 134(5):469-479. PubMed ID: 31217187
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sequential evaluation of CALR mutant burden in patients with myeloproliferative neoplasms.
    Cavalloni C; Rumi E; Ferretti VV; Pietra D; Roncoroni E; Bellini M; Ciboddo M; Casetti IC; Landini B; Fugazza E; Troletti D; Astori C; Cazzola M
    Oncotarget; 2017 May; 8(20):33416-33421. PubMed ID: 28422716
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Selective testing for calreticulin gene mutations in patients with splanchnic vein thrombosis: A prospective cohort study.
    Poisson J; Plessier A; Kiladjian JJ; Turon F; Cassinat B; Andreoli A; De Raucourt E; Goria O; Zekrini K; Bureau C; Lorre F; Cervantes F; Colomer D; Durand F; Garcia-Pagan JC; Casadevall N; Valla DC; Rautou PE; Marzac C;
    J Hepatol; 2017 Sep; 67(3):501-507. PubMed ID: 28483676
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pathological and genomic features of myeloproliferative neoplasms associated with splanchnic vein thrombosis in a single-center cohort.
    Cattaneo D; Bucelli C; Marchetti A; Lionetti M; Fermo E; Bellani V; De Magistris C; Maeda A; Marella A; Primignani M; Consonni D; Gianelli U; Neri A; Baldini L; Bolli N; Iurlo A
    Ann Hematol; 2023 Jun; 102(6):1409-1420. PubMed ID: 37079068
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Clonal evolution in myeloproliferative neoplasms].
    Yoshida K
    Rinsho Ketsueki; 2024; 65(8):784-789. PubMed ID: 39231709
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An accurate, simple prognostic model consisting of age, JAK2, CALR, and MPL mutation status for patients with primary myelofibrosis.
    Rozovski U; Verstovsek S; Manshouri T; Dembitz V; Bozinovic K; Newberry K; Zhang Y; Bove JE; Pierce S; Kantarjian H; Estrov Z
    Haematologica; 2017 Jan; 102(1):79-84. PubMed ID: 27686378
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Clonal hematopoiesis and its evolution of myeloproliferative neoplasms].
    Zhang L; Dong H
    Zhonghua Yi Xue Za Zhi; 2023 Dec; 103(45):3608-3614. PubMed ID: 38018059
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Somatic mutations of calreticulin in myeloproliferative neoplasms.
    Klampfl T; Gisslinger H; Harutyunyan AS; Nivarthi H; Rumi E; Milosevic JD; Them NC; Berg T; Gisslinger B; Pietra D; Chen D; Vladimer GI; Bagienski K; Milanesi C; Casetti IC; Sant'Antonio E; Ferretti V; Elena C; Schischlik F; Cleary C; Six M; Schalling M; Schönegger A; Bock C; Malcovati L; Pascutto C; Superti-Furga G; Cazzola M; Kralovics R
    N Engl J Med; 2013 Dec; 369(25):2379-90. PubMed ID: 24325356
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The clinical and prognostic relevance of driver mutations in 203 Taiwanese patients with primary myelofibrosis.
    Kuo MC; Lin TH; Sun CF; Lin TL; Wu JH; Wang PN; Huang YJ; Chang H; Huang TY; Shih LY
    J Clin Pathol; 2018 Jun; 71(6):514-521. PubMed ID: 29203554
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Analysis of JAK2V617F mutation in Jordanian patients with myeloproliferative neoplasms.
    Jaradat SA; Khasawneh R; Kamal N; Matalka I; Al-Bishtawi M; Al-Sweedan S; Ayesh MH
    Hematol Oncol Stem Cell Ther; 2015 Dec; 8(4):160-6. PubMed ID: 26256826
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Enhanced Risk for Specific Somatic Myeloproliferative Neoplastic Mutations in Patients with Stroke.
    Chen CC; Hsu CC; Huang CE; Chen YY; Lung J; Ho HY; Li CP; Lee JD
    Curr Neurovasc Res; 2017; 14(3):222-231. PubMed ID: 28625126
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Allele-specific polymerase chain reaction and electrophoretic detection in the detection algorithm clinically significant somatic mutations in the gene of calreticulin (calr).].
    Gorbenko AS; Stolyar MA; Olkhovskiy IA; Abdullaev AO; Sudarikov AB; Dunaeva EA; Mironov KO; Shipulin GA
    Klin Lab Diagn; 2018; 63(9):588-592. PubMed ID: 30735328
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Somatic Mutations in Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.
    Ferreira Cristina S; Polo B; Lacerda JF
    Semin Hematol; 2018 Oct; 55(4):215-222. PubMed ID: 30502850
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 38.